A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 456 participants.
Also called NCT02206165
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 456 participants
- Registry
-
NCT02206165
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT02206165. Randomized; double masking; primary purpose treatment. Start 2014-03 (registry gives no type); primary completion 2015-04 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension
- Condition
- Essential Hypertension
- Intervention (Drug)
- Candesartan 8mg
- Intervention (Drug)
- Candesartan 16mg
- Intervention (Drug)
- Amlodipine 5mg
- Intervention (Drug)
- Amlodipine 10mg
- Lead sponsor
- Chong Kun Dang Pharmaceutical
Record details
- Record id
cardio:ct-nct02206165- Content hash
ea1a0ee0f49fae86484cb15db41a3856cb4ab691e7f553cadff9b5ea6199c53b